The entire purpose of using high-purity peptides, like those we supply at Real Peptides, is to eliminate variables
NAFLD can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to NASH, cirrhosis, and cancer
In 2017, the first weekly GLP-1 agonist was approved to help type 2 diabetes
Start gathering: Weight history: office weights, home logs if your clinician accepts them, and timing that shows the trend over time Lifestyle efforts: food tracking, exercise logs, weight-loss program participation, nutrition visits, trainer notes, or written summaries of what youve consistently tried Relevant labs: A1C, lipid panels, and any other clinician-requested labs that help show metabolic risk Problem list support: diagnosed hypertension, type 2 diabetes, dyslipidemia, or other charted conditions connected to treatment need Medication history: prior anti-obesity medications, intolerance, lack of response, or step-therapy attempts if your plan requires them Notice whats missing from that list
